Item 5.02. Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.

On September 7, 2021, the Board of Directors (the "Board") of Berkeley Lights, Inc. (the "Company") increased the authorized number of directors for its Board of Directors from eight (8) to nine (9) and appointed Siddhartha Kadia, Ph.D., to the Board as a Class I director, effective as of September 7, 2021, to serve for a term expiring at the Company's 2024 annual meeting of stockholders. Also effective September 7, 2021, the Board appointed Dr. Kadia to serve as a member of the Audit Committee of the Board, with John Chiminski stepping off of the Audit Committee, and to serve as a member of the Compensation Committee of the Board, with Michael Moritz stepping off of the Compensation Committee.

As provided in the Company's Non-Employee Director Compensation Program, as amended (the "Director Compensation Program"), Dr. Kadia will receive an annual cash retainer of $40,000 per year and additional annual retainers for committee service as described in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 1, 2021 (the "2021 Proxy Statement"). Under the Director Compensation Program, upon the effectiveness of his appointment, Dr. Kadia will be automatically granted an option to purchase 4,900 shares of the Company's common stock (the "Initial Option"), as well as an award of 4,900 restricted stock units (the "Initial RSU Award"), in each case pursuant to the Company's 2020 Incentive Award Plan (the "2020 Plan"). The Initial Option will vest in substantially equal monthly installments for three years from the date of grant, subject to continued service through each applicable vesting date. The Initial RSU Award will vest as to one-third of the restricted stock units on the first anniversary of the grant date and vest thereafter in equal quarterly installments for the following two years, subject to continued service through each applicable vesting date. In addition, following each annual meeting of the Company's stockholders, Dr. Kadia will automatically be granted an option to purchase 4,900 shares of the Company's common stock (the "Annual Option"), as well as an award of 1,400 restricted stock units (the "Annual RSU Award"), in each case pursuant to the 2020 Plan. Each Annual Option and Annual RSU Award will vest in full on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting, subject to continued service through such date. The exercise price per share of the Initial Option and each Annual Option will equal to the fair market value of a share of the Company's common stock on the grant date, and all annual and initial awards will vest in full upon the consummation of a Change in Control (as defined in the 2020 Plan). The Company also entered into the Company's standard indemnification agreement with Dr. Kadia. Please see the descriptions of the Company's standard indemnification agreement and the 2020 Plan contained in the 2021 Proxy Statement for additional information.

There are no arrangements or understandings between Dr. Kadia, on the one hand, and any other persons, on the other hand, pursuant to which Dr. Kadia was selected as a director of the Company. Dr. Kadia is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses